ATE370117T1 - Benzamidliganden für den thyroid-rezeptor - Google Patents

Benzamidliganden für den thyroid-rezeptor

Info

Publication number: ATE370117T1
Authority: AT; Austria
Prior art keywords: carbons; hydrogen; alkyl; trifluoromethyl; cycloalkyl
Prior art date: 2000-06-07

Application number

AT01946036T

Other languages

English (en)

Inventor

Denis Ryono

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-07

Filing date

2001-06-01

Publication date

2007-09-15

2001-06-01 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370117T1 publication Critical patent/ATE370117T1/de

Links

239000003446 ligand Substances 0.000 title abstract 2
102000004217 thyroid hormone receptors Human genes 0.000 title abstract 2
108090000721 thyroid hormone receptors Proteins 0.000 title abstract 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000000217 alkyl group Chemical group 0.000 abstract 3
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
230000001419 dependent effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000004064 dysfunction Effects 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
230000004060 metabolic process Effects 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
230000001105 regulatory effect Effects 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
206010018498 Goitre Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
125000003435 aroyl group Chemical group 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical group 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
201000003872 goiter Diseases 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
208000003532 hypothyroidism Diseases 0.000 abstract 1
230000002989 hypothyroidism Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000000651 prodrug Chemical group 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1
201000002510 thyroid cancer Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Dermatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT01946036T 2000-06-07 2001-06-01 Benzamidliganden für den thyroid-rezeptor ATE370117T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US21010200P	2000-06-07	2000-06-07

Publications (1)

Publication Number	Publication Date
ATE370117T1 true ATE370117T1 (de)	2007-09-15

Family

ID=22781584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01946036T ATE370117T1 (de)	2000-06-07	2001-06-01	Benzamidliganden für den thyroid-rezeptor

Country Status (9)

Country	Link
US (1)	US6395784B1 (de)
EP (1)	EP1292568B1 (de)
JP (1)	JP2004524261A (de)
AT (1)	ATE370117T1 (de)
AU (2)	AU6813201A (de)
CA (1)	CA2411062A1 (de)
DE (1)	DE60129960T2 (de)
ES (1)	ES2291325T3 (de)
WO (1)	WO2001094293A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5763429A (en) *	1993-09-10	1998-06-09	Bone Care International, Inc.	Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) *	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US6566353B2 (en) *	1996-12-30	2003-05-20	Bone Care International, Inc.	Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) *	1996-12-30	2002-09-12	Bone Care International, Inc.	Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) *	1997-02-13	2003-07-10	Bone Care International, Inc.	Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO1999049870A1 (en) *	1998-03-27	1999-10-07	Oregon Health Sciences University	Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
GB9828442D0 (en) *	1998-12-24	1999-02-17	Karobio Ab	Novel thyroid receptor ligands and method II
DE10033494C2 (de) *	2000-07-10	2003-06-26	Handtmann Albert Maschf	Verfahren und Vorrichtung zur Lageänderung von Wurstketten
IL153378A0 (en) *	2000-07-18	2003-07-06	Bone Care Internat Inc	STABILIZED 1alpha-HYDROXY VITAMIN D
US20040242594A1 (en) *	2001-11-17	2004-12-02	Dan Peters	Prodrugs of antidepressants and their use for treating depressions
AU2002351752A1 (en) *	2001-12-29	2003-07-30	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
GB0215978D0 (en) *	2002-07-10	2002-08-21	Karobio Ab	Novel compounds
TW200504021A (en)	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
EP1689383B1 (de)	2003-11-19	2012-10-31	Metabasis Therapeutics, Inc.	Neue phosphor enthaltende thyromimetika
GB0406378D0 (en) *	2004-03-22	2004-04-21	Karobio Ab	Novel pharmaceutical compositions
US7094775B2 (en) *	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) *	2004-06-30	2006-01-05	Bone Care International, Inc.	Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20080069814A1 (en) *	2005-01-05	2008-03-20	Novacea, Inc.	Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AU2006239883A1 (en) *	2005-04-22	2006-11-02	Novacea, Inc.	Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
CA2606499C (en)	2005-05-26	2017-06-13	Metabasis Therapeutics, Inc.	Thyromimetics for the treatment of fatty liver diseases
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US8796282B2 (en) *	2007-03-28	2014-08-05	Case Western Reserve University	Method of treating dermatological disorders
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BRPI1015096A2 (pt) *	2009-04-20	2016-05-03	Mitsubishi Tanabe Pharma Corp	agonista de receptor beta de hormônio tireoideano
DK2470552T3 (en)	2009-08-26	2014-02-17	Sanofi Sa	NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
EP2305239A1 (de) *	2009-09-24	2011-04-06	Assistance Publique, Hopitaux De Paris	Retina-Neuroprotektion durch Ionenkanalhemmer, die durch die Sulfonylharnstoffrezeptor-Untereinheit (SUR) reguliert werden
JP5847533B2 (ja) *	2010-10-19	2016-01-27	田辺三菱製薬株式会社	新規甲状腺ホルモンβ受容体作動薬
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
CA3044059A1 (en)	2016-11-21	2018-05-24	Viking Therapeutics, Inc.	Method of treating glycogen storage disease
EA201992703A1 (ru)	2017-06-05	2020-04-15	Вайкинг Терапьютикс, Инк.	Композиции для лечения фиброза
CA3094167A1 (en)	2018-03-22	2019-09-26	Viking Therapeutics, Inc.	Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en)	2018-12-05	2020-06-11	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis and inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1078582B (de)	1958-10-29	1960-03-31	Hoechst Ag	Verfahren zur Herstellung substituierter Thyropropionsaeuren
GB1561411A (en) *	1977-02-25	1980-02-20	Science Union & Cie	2-phenoxyphenyl pyrrolidines and pharmaceutical compositions containing them
US4741897A (en) *	1986-07-08	1988-05-03	Baxter Travenol	Thyroxine analogs and reagents for thyroid hormone assays
EP0580550B1 (de)	1992-07-21	1997-10-22	Novartis AG	Oxamidsäure-Derivate als hypocholesterämische Mittel
DE69636677D1 (de) *	1995-12-13	2006-12-14	Univ California	Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
GB9713739D0 (en)	1997-06-27	1997-09-03	Karobio Ab	Thyroid receptor ligands
GB9828442D0 (en) *	1998-12-24	1999-02-17	Karobio Ab	Novel thyroid receptor ligands and method II
EP1033364B1 (de)	1999-03-01	2005-02-23	Pfizer Products Inc.	Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
PT1157001E (pt)	1999-03-01	2004-10-29	Pfizer Prod Inc	Acidos oxamicos e derivados como ligandos do receptor da tiroide
CO5160290A1 (es)	1999-03-29	2002-05-30	Novartis Ag	Derivados de acido fenoxifeniloxamico sustituido .
ATE297905T1 (de)	1999-09-30	2005-07-15	Pfizer Prod Inc	6-azauracilderivate als liganden der thyroidrezeptoren

2001
- 2001-05-31 US US09/871,347 patent/US6395784B1/en not_active Expired - Fee Related
- 2001-06-01 WO PCT/US2001/017742 patent/WO2001094293A2/en not_active Ceased
- 2001-06-01 AU AU6813201A patent/AU6813201A/xx active Pending
- 2001-06-01 DE DE60129960T patent/DE60129960T2/de not_active Expired - Lifetime
- 2001-06-01 ES ES01946036T patent/ES2291325T3/es not_active Expired - Lifetime
- 2001-06-01 CA CA002411062A patent/CA2411062A1/en not_active Abandoned
- 2001-06-01 JP JP2002501810A patent/JP2004524261A/ja not_active Ceased
- 2001-06-01 EP EP01946036A patent/EP1292568B1/de not_active Expired - Lifetime
- 2001-06-01 AU AU2001268132A patent/AU2001268132B2/en not_active Ceased
- 2001-06-01 AT AT01946036T patent/ATE370117T1/de active

Also Published As

Publication number	Publication date
AU6813201A (en)	2001-12-17
EP1292568A2 (de)	2003-03-19
DE60129960D1 (de)	2007-09-27
DE60129960T2 (de)	2008-11-06
EP1292568B1 (de)	2007-08-15
WO2001094293A3 (en)	2002-06-06
WO2001094293A2 (en)	2001-12-13
CA2411062A1 (en)	2001-12-13
AU2001268132B2 (en)	2006-05-18
US6395784B1 (en)	2002-05-28
JP2004524261A (ja)	2004-08-12
ES2291325T3 (es)	2008-03-01

Legal Events

Date

Code

Title

Description

2008-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1292568

Country of ref document: EP

Publication	Publication Date	Title
DE60129960D1 (de)	2007-09-27	Benzamidliganden für den thyroid-rezeptor
MY124534A (en)	2006-06-30	Aniline-derived ligands for the thyroid receptor
NZ512422A (en)	2004-02-27	Novel thyroid receptor ligands and method II
YU63301A (sh)	2004-09-03	Oksaminske kiseline i njihovi derivati kao ligandi tiroidnog receptora
JPH01290663A (ja)	1989-11-22	Ｎ―置換イミダゾール、その製造方法およびこれを含有する、エストロゲン原因疾患治療剤
DK1000008T3 (da)	2003-10-20	Hidtil ukendte thyroideareceptorligander og fremgangsmåde
MY137348A (en)	2009-01-30	Highly selective norepinephrine reuptake inhibitors and methods of using the same
NO20010610D0 (no)	2001-02-05	Glukokorticoid- og thyroidhormonreseptorligander for behandling av metabolske lidelser
DE69212058T2 (de)	1997-01-09	Indol-Derivate
CA2126118A1 (en)	1995-02-28	5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative
SE9601677D0 (sv)	1996-05-02	New use
DE3243158A1 (de)	1984-05-24	Neue sulfonsaeureester von hydroxycumarinen, ihre herstellung und sie enthaltende arzneimittel
DE602005002647T2 (de)	2008-07-17	Hexensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
DE69402463T2 (de)	1997-11-27	(7S)-7-(2R)-2-(3-Chlorophenyl)-2-Hydoxyethylamino-5,6,7,8-Tetrahydronaphtalen-2-yloxy Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzungen
IS7649A (is)	2005-01-14	Bensamíð- eða fenýlasetamíðafleiður sem nýtast vel sem viðtakabindlar skjaldkirtilshormóns
DE69521687T2 (de)	2001-10-25	4-indol-1-yl-buttersäure derivate, deren herstellung und deren verwendung als inhibitoren für alpha1-adrenerge rezeptoren und testosteron 5alpha-reduktasen
DE69204908T2 (de)	1996-02-08	2-Hydroxy-2-phenylethylaminderivate als Beta-3-adrenoceptor Agonisten.
ATE289583T1 (de)	2005-03-15	Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
DK0804186T3 (da)	2002-06-17	Indolditerpenalkaloidforbindelser
MX9707596A (es)	1998-06-30	Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
CA2494176A1 (en)	2004-04-01	Intermediates in producing phenoxyacetic acid derivatives and method of using the same
DE1618849B1 (de)	1971-12-23	Phenylisopropylamidverbindungen und Verfahren zu ihrer Herstellung
KR880011163A (ko)	1988-10-26	4- 벤질- 피페라지닐 하이드라존
MX2025011371A (es)	2025-12-01	(s)-tianeptina y uso en tratamiento de trastornos y afecciones asociadas con el receptor activado por proliferador de peroxisoma
FR2558159A1 (fr)	1985-07-19	3-alkoxy 2-(n-pyrrolidino)-n-pyridyl-n-arylmethyl-propylamines, leur preparation et leur application en therapeutique